RNAlead, Disrupting RNA Delivery with a Proven Alternative
RNAlead was created to offer our clients strategic access to a cutting-edge, proprietary RNA delivery platform through licensing solutions. Designed to be more efficient, more accessible, and future-ready, our platform sets a new standard for RNA-based therapeutics.
Leading the Next Frontier of Therapeutic Innovation
At the heart of our innovation lies the versatility of our RNA delivery system, enabling a wide range of therapeutic applications. This adaptability positions RNAlead as a key player in the biotherapy market, offering a strong competitive edge and opening new frontiers for next-generation treatments.
The scientific expertise at RNAlead is fueled by a dedicated team of experienced professionals who strongly believe that our extensive experience with the FlashRNA® technology qualifies us as the ideal partner for (co)developing new and innovative therapies with you. We are dedicated to addressing the challenges posed by new projects with agility, expertise, tailor-made approach and enthusiasm. We firmly believe that our extensive experience with FlashRNA® technology qualifies us as the ideal partners for developing new and innovative therapies.
Our objective is to ensure broad access to efficient solutions for tomorrow’s medicine through RNA delivery.
Christine Duthoit, PhD CEO – CSO
RNAlead was born from a strong conviction : biotherapy needs smarter, more accessible delivery solutions to meet tomorrow’s challenges. With FlashRNA®, we’ve built a proprietary technology designed to reshape the rules of the game.
Our ambition is clear — to be a key player in tomorrow’s medicine, alongside the innovators who dare to lead.
Valentin Alsat CFO – COO
Our history
2015-2018
PROTECTING TECHNOLOGY
Three patent applications to protect the FlashRNA® technology
2019-2024
FIRST CLINICAL TRIAL BUILT WITH FLASHRNA®
LymphARN clinical trial, using FlashRNA®as a drug product
02/2025
CREATION
Creation of RNAlead to bring our alternative RNA transfer technology to market
2025-2026
GO FOR FIRST IN HUMAN
Launch of phase I LymphRNA with the first injection scheduled for late 2025 – interim results in the first quarter of 2026
Our team
A dedicated team of 7 passionate professionals, combining deep, cross-functional expertise in our proprietary technology in FlashRNA® technology and its R&D to GMP production process — built on a strong foundation of shared experience and a unified vision.
RNAlead is supported by two key governance bodies: a world-renowned scientific advisory committee and a strategic committee composed of seasoned industry leaders. The scientific advisory committee helps define our research and development priorities and assess the relevance of our innovations. The strategic committee supports our growth by advising us on development, financing, and partnerships to ensure that FlashRNA® evolves in line with market and therapeutic needs.
